PT3521282T - Derivados de quinazolina utilizados para tratar vih - Google Patents

Derivados de quinazolina utilizados para tratar vih

Info

Publication number
PT3521282T
PT3521282T PT182133090T PT18213309T PT3521282T PT 3521282 T PT3521282 T PT 3521282T PT 182133090 T PT182133090 T PT 182133090T PT 18213309 T PT18213309 T PT 18213309T PT 3521282 T PT3521282 T PT 3521282T
Authority
PT
Portugal
Prior art keywords
derivatives used
quinazoline derivatives
treat hiv
hiv
treat
Prior art date
Application number
PT182133090T
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Inst Of Organic Chemistry And Biochemistry As Cr V V I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Inst Of Organic Chemistry And Biochemistry As Cr V V I filed Critical Gilead Sciences Inc
Publication of PT3521282T publication Critical patent/PT3521282T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT182133090T 2014-12-24 2015-12-23 Derivados de quinazolina utilizados para tratar vih PT3521282T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462096748P 2014-12-24 2014-12-24

Publications (1)

Publication Number Publication Date
PT3521282T true PT3521282T (pt) 2021-11-29

Family

ID=55305044

Family Applications (2)

Application Number Title Priority Date Filing Date
PT182133090T PT3521282T (pt) 2014-12-24 2015-12-23 Derivados de quinazolina utilizados para tratar vih
PT15832711T PT3237398T (pt) 2014-12-24 2015-12-23 Derivados de quinazolina utilizados para tratar vih

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT15832711T PT3237398T (pt) 2014-12-24 2015-12-23 Derivados de quinazolina utilizados para tratar vih

Country Status (41)

Country Link
US (5) US9730936B2 (pt)
EP (4) EP4302830A3 (pt)
JP (2) JP6367489B2 (pt)
KR (2) KR102288855B1 (pt)
CN (2) CN107278201B (pt)
AR (1) AR103252A1 (pt)
AU (1) AU2015371198B2 (pt)
BR (1) BR102015032361B1 (pt)
CA (1) CA2972021C (pt)
CL (1) CL2017001675A1 (pt)
CO (1) CO2017006214A2 (pt)
CR (1) CR20170281A (pt)
CU (1) CU20170089A7 (pt)
CY (1) CY1124726T1 (pt)
DK (1) DK3521282T3 (pt)
DO (1) DOP2017000151A (pt)
EA (2) EA035746B1 (pt)
EC (1) ECSP17039611A (pt)
ES (3) ES2900810T3 (pt)
HK (1) HK1244001B (pt)
HR (1) HRP20211543T1 (pt)
HU (1) HUE058296T2 (pt)
IL (2) IL253059B (pt)
LT (1) LT3521282T (pt)
MA (1) MA48448A (pt)
MD (1) MD4650B1 (pt)
MX (2) MX367574B (pt)
MY (1) MY189761A (pt)
NZ (1) NZ733174A (pt)
PE (1) PE20171306A1 (pt)
PH (1) PH12017501191A1 (pt)
PL (3) PL3237398T3 (pt)
PT (2) PT3521282T (pt)
SA (1) SA517381826B1 (pt)
SG (2) SG10202101143VA (pt)
SI (2) SI3521282T1 (pt)
SV (1) SV2017005471A (pt)
TR (1) TR201903672T4 (pt)
TW (3) TW202237569A (pt)
UA (1) UA117796C2 (pt)
WO (1) WO2016105564A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のための化合物
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
NZ733135A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
KR102180740B1 (ko) 2016-08-19 2020-11-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
CA3089590C (en) 2018-02-15 2022-12-06 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
AR114631A1 (es) 2018-02-16 2020-09-30 Gilead Sciences Inc Métodos e intermedios para preparar compuestos de piridina
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
JP2023502530A (ja) 2019-11-26 2023-01-24 ギリアード サイエンシーズ, インコーポレイテッド Hiv予防のためのカプシド阻害剤
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US20220340553A1 (en) 2020-04-24 2022-10-27 Sumito Pharma Co., Ltd. 2-heteroaryl aminoquinazolinone derivative
WO2021262990A1 (en) 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
US20230212148A1 (en) 2021-12-03 2023-07-06 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
US20230203071A1 (en) 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197420A (en) 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
WO2001021598A1 (en) 1999-09-23 2001-03-29 Astrazeneca Ab Therapeutic quinazoline compounds
BR0015718A (pt) 1999-11-22 2002-07-23 Warner Lambert Co Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
US7547702B2 (en) 2000-09-20 2009-06-16 Ortho-Mcneil Pharmaceutical, Inc. 4-amino-quinazolines
WO2004030672A1 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
WO2004108711A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
HUE043207T2 (hu) 2004-07-27 2019-08-28 Gilead Sciences Inc HIV-gátló vegyületek foszfonát analógjai
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
WO2006099301A2 (en) 2005-03-10 2006-09-21 The Regents Of The University Of California Apoptosis inhibitors
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
MX2008000017A (es) 2005-06-28 2008-03-26 Sanofi Aventis Derivados de isoquinolina como inhibidores de rho-cinasa.
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP2476669A1 (en) 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換2−アミノ縮合複素環式化合物
DE602007006835D1 (de) 2006-07-20 2010-07-08 Amgen Inc Substituierte pyridonverbindungen und anwendungsverfahren
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JPWO2008050808A1 (ja) 2006-10-24 2010-02-25 協和発酵キリン株式会社 2−アミノキナゾリン誘導体
PT2125744E (pt) 2006-12-27 2011-07-01 Sanofi Aventis Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina
MY155009A (en) 2006-12-27 2015-08-28 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
BRPI0720862A2 (pt) 2006-12-27 2014-02-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
US20090004185A1 (en) 2007-01-11 2009-01-01 Wyeth Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
BRPI0809913A2 (pt) 2007-04-06 2014-10-07 Novartis Ag Derivados de 2,6-naftiridina como moduladores da proteína quinase
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
UA100250C2 (uk) 2007-11-16 2012-12-10 Гілеад Сайнсіз, Інк. Інгібітори реплікації вірусу імунодефіциту людини
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
EP2315627B1 (de) 2008-08-15 2014-10-15 Basf Se Verfahren zur herstellung von nanoskaligen organischen feststoffpartikeln
EP2364314B1 (en) 2008-12-09 2014-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
PE20120424A1 (es) 2008-12-29 2012-05-04 Fovea Pharmaceuticals Compuestos de quinazolina sustituidos
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (en) 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
WO2011163610A2 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
JP5806735B2 (ja) 2010-07-02 2015-11-10 ギリアード サイエンシーズ, インコーポレイテッド Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体
CA2802308C (en) 2010-07-02 2018-08-28 Lianhong Xu Napht-2-ylacetic acid derivatives to treat aids
KR20130141500A (ko) 2010-09-29 2013-12-26 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
KR20120038060A (ko) 2010-10-13 2012-04-23 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
KR20130129244A (ko) 2010-12-17 2013-11-27 에프. 호프만-라 로슈 아게 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
MD20140063A2 (ro) 2012-04-20 2014-12-31 Gilead Sciences, Inc. Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
CA3012242C (en) 2012-12-21 2021-11-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
SG11201504982PA (en) 2012-12-27 2015-07-30 Japan Tobacco Inc SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
EP2769723A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
NZ733135A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv

Also Published As

Publication number Publication date
US10206926B2 (en) 2019-02-19
PT3237398T (pt) 2019-03-06
KR102049476B1 (ko) 2019-11-28
UA117796C2 (uk) 2018-09-25
IL269635B (en) 2021-04-29
AU2015371198A1 (en) 2017-07-13
EP3237398B1 (en) 2018-12-19
US11304948B2 (en) 2022-04-19
CU20170089A7 (es) 2017-11-07
US20160250215A1 (en) 2016-09-01
ECSP17039611A (es) 2017-07-31
US10548898B2 (en) 2020-02-04
WO2016105564A8 (en) 2016-10-06
CN107278201B (zh) 2020-05-19
WO2016105564A1 (en) 2016-06-30
SA517381826B1 (ar) 2021-10-21
HK1244001B (zh) 2020-01-10
CY1124726T1 (el) 2022-07-22
KR20190133068A (ko) 2019-11-29
SI3521282T1 (sl) 2021-11-30
CA2972021A1 (en) 2016-06-30
US20200360383A1 (en) 2020-11-19
IL253059B (en) 2019-10-31
PH12017501191B1 (en) 2018-03-05
EP3521282B1 (en) 2021-08-25
CR20170281A (es) 2017-11-08
EP4302830A2 (en) 2024-01-10
MD4650B1 (ro) 2019-09-30
SG10202101143VA (en) 2021-03-30
ES2964395T3 (es) 2024-04-05
EP3237398A1 (en) 2017-11-01
SG11201705215PA (en) 2017-07-28
IL269635A (en) 2019-11-28
CA2972021C (en) 2020-04-28
EP3960735C0 (en) 2023-09-13
DOP2017000151A (es) 2017-09-15
MX367574B (es) 2019-08-27
CN107278201A (zh) 2017-10-20
US20170354656A1 (en) 2017-12-14
BR102015032361A2 (pt) 2016-07-05
TW201636328A (zh) 2016-10-16
DK3521282T3 (da) 2021-09-27
TW202106667A (zh) 2021-02-16
TW202237569A (zh) 2022-10-01
ES2900810T3 (es) 2022-03-18
SI3237398T1 (sl) 2019-04-30
HUE058296T2 (hu) 2022-07-28
JP6367489B2 (ja) 2018-08-01
US20190134035A1 (en) 2019-05-09
MY189761A (en) 2022-03-03
PL3521282T3 (pl) 2022-01-03
PL3960735T3 (pl) 2024-03-18
TWI699355B (zh) 2020-07-21
US20230043136A1 (en) 2023-02-09
BR102015032361B1 (pt) 2021-12-21
ES2715507T3 (es) 2019-06-04
AR103252A1 (es) 2017-04-26
NZ733174A (en) 2018-12-21
BR102015032361A8 (pt) 2021-08-31
KR102288855B1 (ko) 2021-08-11
PL3237398T3 (pl) 2019-05-31
MX2019009932A (es) 2019-10-02
CL2017001675A1 (es) 2018-05-11
TWI770552B (zh) 2022-07-11
EA201791256A1 (ru) 2018-04-30
PH12017501191A1 (en) 2018-03-05
EA202091115A1 (ru) 2021-01-29
KR20170131351A (ko) 2017-11-29
CN111574464A (zh) 2020-08-25
CO2017006214A2 (es) 2017-10-20
JP2018500358A (ja) 2018-01-11
MX2017008521A (es) 2018-03-01
PE20171306A1 (es) 2017-09-05
LT3521282T (lt) 2021-11-25
HRP20211543T1 (hr) 2022-01-07
US9730936B2 (en) 2017-08-15
EP3960735A1 (en) 2022-03-02
EP3960735B1 (en) 2023-09-13
EP4302830A3 (en) 2024-03-13
MD20170070A2 (ro) 2017-12-31
EA035746B1 (ru) 2020-08-05
JP2018168181A (ja) 2018-11-01
IL253059A0 (en) 2017-08-31
EP3521282A1 (en) 2019-08-07
AU2015371198B2 (en) 2018-09-27
TR201903672T4 (tr) 2019-04-22
SV2017005471A (es) 2018-01-18
MA48448A (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
IL269635B (en) History of conazole used to treat hiv
HK1246776A1 (zh) 用於hiv治療的異喹啉化合物
HK1245092A1 (zh) 膏藥
HK1257272A1 (zh) 治療hiv的工具
SG11201606199SA (en) Ketoprofen-containing poultice
HUE050165T2 (hu) Etilén-glikolok MMF származékai
GB2522473B (en) Improvements to windposts
GB2522039B (en) I-beam
AU5296P (en) LowstenoGL Grevillea stenomera
AU5297P (en) FlatstenoGL Grevillea stenomera
GB2520781B (en) Improvements to hydro-turbines
AU2014903428A0 (en) Treatment of HIV
GB201414186D0 (en) Secure tip
GB201421232D0 (en) Retro-reflector
GB201405489D0 (en) Able to go
GB201409013D0 (en) My site
GB201409028D0 (en) Easy see mouse
GB201406790D0 (en) Laser treatment
GB201401124D0 (en) Anti-inflammatory solution
GB201400235D0 (en) Treatment